13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001618205
Total reported value
$213.8M
$213.8M
68 檔
31.2%
The Q4 2025 SEC filing reveals that Birchview Capital, LP held a total portfolio value of $213.8M, covering 68 public equity positions.
Birchview Capital, LP executed strategic sector rebalancing during Q4 2025, establishing 11 new positions while fully exiting 12 holdings and trimming 14 positions.
In terms of portfolio concentration, the top 5 core holdings (including KLAC, BMY, CMPX) accounted for 31.2% of total reported equity market value during Q4 2025.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | KLAC | Kla CORP | Stock-Tech | 15.57% | +8.51% | — | |
| 2 | BMY | Bristol-myers Squibb Co | Stock-Healthcare | 9.56% | -2.56% | -4.42% | |
| 3 | CMPX | Compass Therapeutics Inc | Stock-Other | 5.01% | -2.69% | +82.48% | |
| 4 | STOK | Stoke Therapeutics Inc | Stock-Other | 4.83% | -1.16% | +23.81% | |
| 5 | LRCX | Lam Research CORP | Stock-Tech | 4.04% | +2.71% | — | |
| 6 | OLMA | Olema Pharmaceuticals Inc | Stock-Other | 3.94% | -0.70% | +54.60% | |
| 7 | GPCR | Structure Therapeutics Inc | Stock-Other | 3.66% | -2.14% | +15.38% | |
| 8 | PTGX | Protagonist Therapeutics Inc | Stock-Other | 2.81% | -0.09% | +14.58% | |
| 9 | ACAD | Acadia Pharmaceuticals Inc | Stock-Healthcare | 2.67% | -0.15% | — | |
| 10 | OVV | Ovintiv Inc | Stock-Energy | 2.47% | -0.98% | — | |
| 11 | PRTA | Prothena Corporation plc | Stock-Other | 2.47% | -0.42% | -19.67% | |
| 12 | SLDB | Solid Biosciences Inc | Stock-Other | 2.33% | +0.54% | +137.73% | |
| 13 | NBIX | Neurocrine Biosciences Inc | Stock-Healthcare | 2.26% | +0.10% | -5.23% | |
| 14 | AM6 | Amicus Therapeutics Inc | Stock-Other | 2.11% | — | — | |
| 15 | BCYC | Bicycle Therapeutics Plc-adr | Stock-Other | 1.92% | -0.60% | +200.45% | |
| 16 | PHAT | Phathom Pharmaceuticals Inc | Stock-Other | 1.89% | -0.95% | +129.41% | |
| 17 | CSTL | Castle Biosciences Inc | Stock-Other | 1.84% | -0.04% | -27.12% | |
| 18 | NTLA | Intellia Therapeutics Inc | Stock-Other | 1.66% | -0.08% | +425.67% | |
| 19 | IMNM | Immunome Inc | Stock-Other | 1.63% | -0.12% | +23.81% | |
| 20 | CORT | Corcept Therapeutics Inc | Stock-Healthcare | 1.37% | +1.25% | — | |
| 21 | VERA | Vera Therapeutics Inc | Stock-Other | 1.30% | +0.15% | — | |
| 22 | QDELUSD | Quidelortho CORP | Stock-Other | 1.21% | -0.04% | — | |
| 23 | NVCR | NovoCure Limited | Stock-Healthcare | 1.15% | -1.26% | EXIT | |
| 24 | ✓ | Biodesix Inc | Stock-Other | 1.14% | +0.65% | — | |
| 25 | CYTK | Cytokinetics Inc | Stock-Healthcare | 1.12% | +0.07% | — | |
| 26 | PHR | Phreesia Inc | Stock-Other | 1.10% | -0.07% | EXIT | |
| 27 | EQT | Eqt CORP | Stock-Energy | 1.09% | -0.39% | — | |
| 28 | HROW | Harrow Inc | Stock-Other | 0.98% | — | -15.00% | |
| 29 | TVTX | Travere Therapeutics Inc | Stock-Other | 0.96% | +0.28% | -0.14% | |
| 30 | FHTX | Foghorn Therapeutics Inc | Stock-Other | 0.89% | -0.13% | — | |
| 31 | UTHR | United Therapeutics CORP | Stock-Healthcare | 0.86% | -0.38% | — | |
| 32 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 0.83% | -0.74% | EXIT | |
| 33 | ALKS | Alkermes plc | Stock-Healthcare | 0.82% | +0.22% | — | |
| 34 | NKTR | Nektar Therapeutics | Stock-Other | 0.77% | +1.37% | +670.95% | |
| 35 | APGE | Apogee Therapeutics Inc | Stock-Other | 0.71% | -0.43% | EXIT | |
| 36 | VSTM | Verastem Inc | Stock-Other | 0.68% | -0.45% | EXIT | |
| 37 | AXSM | Axsome Therapeutics Inc | Stock-Healthcare | 0.65% | +0.11% | +1.02% | |
| 38 | MASI* | Masimo CORP | Stock-Other | 0.63% | — | — | |
| 39 | TXG | 10x Genomics Inc-class A | Stock-Other | 0.56% | — | — | |
| 40 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 0.55% | -0.11% | — | |
| 41 | PACB | Pacific Biosciences Of Calif | Stock-Other | 0.55% | -0.07% | — | |
| 42 | 4XC1 | Kalvista Pharmaceuticals Inc | Stock-Other | 0.54% | -0.65% | EXIT | |
| 43 | FCX | Freeport-mcmoran Inc | Stock-Materials | 0.54% | -0.07% | +0.01% | |
| 44 | VTYXUSD | Ventyx Biosciences Inc | Stock-Other | 0.53% | — | +2.02% | |
| 45 | PHVS | Pharvaris N.V. | Stock-Other | 0.48% | — | +101.03% | |
| 46 | ILMN | Illumina Inc | Stock-Healthcare | 0.46% | — | — | |
| 47 | QURE | uniQure N.V. | Stock-Other | 0.43% | +0.15% | -60.89% | |
| 48 | HALO | Halozyme Therapeutics Inc | Stock-Healthcare | 0.40% | +0.85% | — | |
| 49 | BHVN | Biohaven Ltd. | Stock-Other | 0.39% | — | — | |
| 50 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 0.39% | -0.07% | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | CMPX | Compass Therapeutics Inc | +2.7% | +82.48% | Add |
| 2 | OLMA | Olema Pharmaceuticals Inc | +2.7% | +54.60% | Add |
| 3 | GPCR | Structure Therapeutics Inc | +2% | +15.38% | Add |
| 4 | PHAT | Phathom Pharmaceuticals Inc | +1.1% | +129.41% | Add |
| 5 | STOK | Stoke Therapeutics Inc | +1.1% | +23.81% | Add |
| 6 | BCYC | Bicycle Therapeutics Plc-adr | +1% | +200.45% | Add |
| 7 | SLDB | Solid Biosciences Inc | +1% | +137.73% | Add |
| 8 | NTLA | Intellia Therapeutics Inc | +0.9% | +425.67% | Add |
| 9 | IMNM | Immunome Inc | +0.7% | +23.81% | Add |
| 10 | AM6 | Amicus Therapeutics Inc | +0.6% | — | Unchanged |
| 11 | NKTR | Nektar Therapeutics | +0.6% | +670.95% | Add |
| 12 | PTGX | Protagonist Therapeutics Inc | +0.4% | +14.58% | Add |
| 13 | RARE | Ultragenyx Pharmaceutical In | +0.3% | +181.82% | Add |
| 14 | VTYXUSD | Ventyx Biosciences Inc | +0.3% | +2.02% | Add |
| 15 | APGE | Apogee Therapeutics Inc | +0.2% | — | Unchanged |
| 16 | PHVS | Pharvaris N.V. | +0.2% | +101.03% | Add |
| 17 | TVTX | Travere Therapeutics Inc | +0.2% | -0.14% | Trim |
| 18 | NVCR | NovoCure Limited | +0.2% | +48.97% | Add |
| 19 | AXSM | Axsome Therapeutics Inc | +0.1% | +1.02% | Add |
| 20 | PACB | Pacific Biosciences Of Calif | +0.1% | — | Unchanged |
| 21 | BBIO | Bridgebio Pharma Inc | +0.1% | — | Unchanged |
| 22 | CGEM | Cullinan Therapeutics Inc | 0% | — | Unchanged |
| 23 | ALMS | Alumis Inc | 0% | — | Unchanged |
| 24 | FCX | Freeport-mcmoran Inc | 0% | +0.01% | Add |
| 25 | ZNTL | Zentalis Pharmaceuticals Inc | 0% | — | Unchanged |
| 26 | GOSS | Gossamer Bio Inc | 0% | — | Unchanged |
| 27 | APLSUSD | Apellis Pharmaceuticals Inc | 0% | — | Unchanged |
| 28 | CADL | Candel Therapeutics Inc | 0% | — | Unchanged |
| 29 | CSTL | Castle Biosciences Inc | -0.1% | -27.12% | Trim |
| 30 | 4XC1 | Kalvista Pharmaceuticals Inc | -0.1% | -14.93% | Trim |
| 31 | ACAD | Acadia Pharmaceuticals Inc | -0.1% | — | Unchanged |
| 32 | UTHR | United Therapeutics CORP | -0.1% | — | Unchanged |
| 33 | XENE | Xenon Pharmaceuticals Inc | -0.1% | — | Unchanged |
| 34 | CYTK | Cytokinetics Inc | -0.1% | — | Unchanged |
| 35 | ATEC | Alphatec Holdings Inc | -0.1% | -45.28% | Trim |
| 36 | FHTX | Foghorn Therapeutics Inc | -0.2% | — | Unchanged |
| 37 | HALO | Halozyme Therapeutics Inc | -0.2% | — | Unchanged |
| 38 | MASI* | Masimo CORP | -0.3% | — | Unchanged |
| 39 | VYGR | Voyager Therapeutics Inc | -0.3% | -44.47% | Trim |
| 40 | ALKS | Alkermes plc | -0.3% | — | Unchanged |
| 41 | EQT | Eqt CORP | -0.3% | — | Unchanged |
| 42 | ELUT | Elutia Inc | -0.4% | -63.02% | Trim |
| 43 | QDELUSD | Quidelortho CORP | -0.4% | — | Unchanged |
| 44 | HROW | Harrow Inc | -0.5% | -15.00% | Trim |
| 45 | ✓ | Biodesix Inc | -0.5% | — | Unchanged |
| 46 | TMCI | Treace Medical Concepts Inc | -0.6% | +28.26% | Add |
| 47 | OMGBP | Outset Medical Inc | -0.6% | +25.87% | Add |
| 48 | INBX | Inhibrx Biosciences Inc | -0.6% | -88.33% | Trim |
| 49 | DCGO | Docgo Inc | -0.8% | -93.47% | Trim |
| 50 | NBIX | Neurocrine Biosciences Inc | -0.8% | -5.23% | Trim |
According to official SEC Form 13F filings, Birchview Capital, LP reported a total U.S. public equity portfolio value of $213.8M across 68 disclosed positions in Q4 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Top New Position Initiated
LRCX
市值: $6.9M
Top Position Liquidated / Trimmed
AXGN
前期市值: $2.1M
During Q4 2025, Birchview Capital, LP's top holdings by market value included KLAC (15.6%)、BMY (9.6%)、CMPX (5.0%). The largest single position, KLAC, represented 15.6% of total portfolio value.
In Q4 2025, Birchview Capital, LP made 56 total portfolio adjustments, initiating 11 new buys, adding to 19 positions, trimming 14 holdings, and fully liquidating 12 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.